Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
2seventy bio, Inc. - Common Stock
(NQ:
TSVT
)
4.874
+0.124 (+2.60%)
Streaming Delayed Price
Updated: 9:42 AM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 2seventy bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
August 07, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
August 05, 2024
From
2seventy bio, Inc.
Via
Business Wire
3 Hidden Stock Gems That Wall Street Is Overlooking
July 05, 2024
If you play the long game and have a suitable risk tolerance, you can find overlooked stock gems like these three.
Via
InvestorPlace
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
June 27, 2024
2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on...
Via
Benzinga
A Preview Of 2seventy bio's Earnings
March 04, 2024
Via
Benzinga
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
June 26, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
May 23, 2024
From
2seventy bio, Inc.
Via
Business Wire
TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024
May 08, 2024
TSVT stock results show that 2seventy bio met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
May 08, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
May 03, 2024
From
2seventy bio, Inc.
Via
Business Wire
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
April 19, 2024
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel
Via
Benzinga
Exposures
Product Safety
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
April 05, 2024
FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard...
Via
Benzinga
Exposures
Product Safety
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
April 01, 2024
From
2seventy bio, Inc.
Via
Business Wire
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
April 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
March 20, 2024
From
2seventy bio, Inc.
Via
Business Wire
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 18, 2024
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates.
Via
Benzinga
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
March 18, 2024
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 18, 2024
Via
Benzinga
Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
March 18, 2024
Shares of Nuvei Corp (NASDAQ: NVEI) rose sharply in today’s pre-market trading following a report indicating the company is in buyout talks with Advent International. Nuvei shares jumped 14.1% to...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
March 18, 2024
Pre-market stock movers are the perfect way to start the week as we dive into the biggest stories moving shares on Monday!
Via
InvestorPlace
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
March 15, 2024
From
Bristol Myers Squibb
Via
Business Wire
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
March 15, 2024
Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings.
Via
Benzinga
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
March 07, 2024
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.
Via
Benzinga
TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023
March 05, 2024
TSVT stock results show that 2seventy bio missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
March 05, 2024
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
March 01, 2024
From
2seventy bio, Inc.
Via
Business Wire
Earnings Scheduled For March 5, 2024
March 05, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
Via
Benzinga
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
February 27, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...
Via
Newsfile
2seventy bio to Participate in Upcoming Investor Conferences
February 05, 2024
From
2seventy bio, Inc.
Via
Business Wire
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
February 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.